Literature DB >> 27090896

[Guideline-adherent inpatient psychiatric psychotherapeutic treatment of obsessive-compulsive disorder : Normative definition of personnel requirements].

J P Klein1, B Zurowski2, J Wolff3, F Godemann4, S C Herpertz5, M Berger6, G Heuft7, F Hohagen2.   

Abstract

BACKGROUND: Guideline-oriented inpatient psychiatric and psychotherapeutic treatment of patients with obsessive-compulsive disorder (OCD) is an important part of the care available for these patients. It may not be adequately reflected in the current personnel resources available according to the German psychiatry personnel regulation (Psych-PV).
OBJECTIVES: The goal of this work was to assess the personnel resources necessary for a guideline-oriented inpatient psychiatric and psychotherapeutic treatment of patients with OCD and compare the necessary resources with the resources available according to Psych-PV.
METHODS: Based on the German national guidelines for OCD and a meta-analysis on treatment intensity, we formulated a normative weekly treatment plan. Based on this plan we calculated the necessary personnel resources and compared these with the resources available according to Psych-PV category A1 (standard care).
RESULTS: The weekly treatment time for a guideline-oriented inpatient psychiatric and psychotherapeutic treatment of patients with OCD is 23.5 h per week. This corresponds to a weekly personnel requirement of 20.9 h. This requirement is only partly reflected in the Psych-PV (17.3 h, 82.8 %). The coverage of personnel resources by Psych-PV is even lower for psychotherapy provided by psychiatrist and psychologists (38.3 %, i. e. 183 min in the normative plan versus 70 min in Psych-PV).
CONCLUSIONS: The current paper shows that the personal resources required for a guideline-oriented inpatient psychiatric and psychotherapeutic treatment of patients with OCD is not adequately reflected in the German psychiatry personnel regulation (Psych-PV). The actual shortage may be underestimated in our paper.

Entities:  

Keywords:  Inpatient treatment; Lump-sum payment system in psychiatry and psychosomatic medicine; Obsessive-compulsive disorder; PEPP; Psych-PV; Psychiatry personnel regulation; Psychotherapy

Mesh:

Year:  2016        PMID: 27090896     DOI: 10.1007/s00115-016-0112-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  16 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

2.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.

Authors:  Maximilian Huhn; Magdolna Tardy; Loukia Maria Spineli; Werner Kissling; Hans Förstl; Gabriele Pitschel-Walz; Claudia Leucht; Myrto Samara; Markus Dold; John M Davis; Stefan Leucht
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

4.  A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns].

Authors:  G Skoog; I Skoog
Journal:  Arch Gen Psychiatry       Date:  1999-02

5.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

6.  Treatment of severe, treatment-refractory obsessive-compulsive disorder: a study of inpatient and community treatment.

Authors:  Mark J Boschen; Lynne M Drummond; Anusha Pillay
Journal:  CNS Spectr       Date:  2008-12       Impact factor: 3.790

7.  Helpseeking and access to mental health treatment for obsessive-compulsive disorder.

Authors:  Renee Goodwin; Karestan C Koenen; Fred Hellman; Mary Guardino; Elmer Struening
Journal:  Acta Psychiatr Scand       Date:  2002-08       Impact factor: 6.392

8.  Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000.

Authors:  Albina R Torres; Martin J Prince; Paul E Bebbington; Dinesh Bhugra; Traolach S Brugha; Michael Farrell; Rachel Jenkins; Glyn Lewis; Howard Meltzer; Nicola Singleton
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

9.  Clinical and treatment comparisons between adults with early- and late-onset obsessive-compulsive disorder.

Authors:  Claire L Lomax; Victoria B Oldfield; Paul M Salkovskis
Journal:  Behav Res Ther       Date:  2008-10-22

10.  Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH).

Authors:  Frank Jacobi; Michael Höfler; Jens Siegert; Simon Mack; Anja Gerschler; Lucie Scholl; Markus A Busch; Ulfert Hapke; Ulrike Maske; Ingeburg Seiffert; Wolfgang Gaebel; Wolfgang Maier; Michael Wagner; Jürgen Zielasek; Hans-Ulrich Wittchen
Journal:  Int J Methods Psychiatr Res       Date:  2014-04-11       Impact factor: 4.035

View more
  2 in total

1.  [Activities without patient contact : Estimate of time costs based on telephone interviews in eight psychiatric hospitals].

Authors:  A Blume; P Brückner-Bozetti; T Steinert
Journal:  Nervenarzt       Date:  2018-07       Impact factor: 1.214

2.  [Rationing in inpatient psychiatric care].

Authors:  B Braun; P Brückner-Bozetti; M Lingenfelder; C Uhlmann; T Steinert
Journal:  Nervenarzt       Date:  2017-09       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.